This study, called LIVER-R, is observing how durvalumab-based treatments work for people with hepatobiliary cancers (cancers of the liver, gallbladder, or bile ducts) in real-world settings. Researchers are collecting information on patients who are already receiving durvalumab-based regimens, such as STRIDE or durvalumab combined with chemotherapy (like GemCis). The study aims to understand how long patients live after starting these treatments. You may be able to join if you are an adult (18 years or older) with a confirmed hepatobiliary cancer that your doctor has decided to treat with a durvalumab-based regimen. The study is currently unclear on its recruitment status.

Study design

This is an observational study, meaning researchers will collect information from your routine medical care. It aims to include about 4490 participants across many countries.

What's involved

Data will be collected during your routine doctor visits and from your medical records. This will happen at enrollment and at 6-month intervals.

Compensation

Not stated in the trial record.

Follow-up

You will be followed for up to 2 years if you have advanced biliary tract cancer, or up to 3 years if you have unresectable hepatocellular carcinoma.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.